35,613 results on '"Sars-Cov-2"'
Search Results
352. Surface Plasmon Resonance Immunosensor for Direct Detection of Antibodies against SARS-CoV-2 Nucleocapsid Protein.
- Author
-
Lisyte, Viktorija, Kausaite-Minkstimiene, Asta, Brasiunas, Benediktas, Popov, Anton, and Ramanaviciene, Almira
- Subjects
- *
DETECTION limit , *IMMUNE response , *SARS-CoV-2 , *IMMUNOGLOBULINS , *MONOCLONAL antibodies , *SURFACE plasmon resonance - Abstract
The strong immunogenicity of the SARS-CoV-2 nucleocapsid protein is widely recognized, and the detection of specific antibodies is critical for COVID-19 diagnostics in patients. This research proposed direct, label-free, and sensitive detection of antibodies against the SARS-CoV-2 nucleocapsid protein (anti-SCoV2-rN). Recombinant SARS-CoV-2 nucleocapsid protein (SCoV2-rN) was immobilized by carbodiimide chemistry on an SPR sensor chip coated with a self-assembled monolayer of 11-mercaptoundecanoic acid. When immobilized under optimal conditions, a SCoV2-rN surface mass concentration of 3.61 ± 0.52 ng/mm2 was achieved, maximizing the effectiveness of the immunosensor for the anti-SCoV2-rN determination. The calculated KD value of 6.49 × 10−8 ± 5.3 × 10−9 M confirmed the good affinity of the used monoclonal anti-SCoV2-rN antibodies. The linear range of the developed immunosensor was from 0.5 to 50 nM of anti-SCoV2-rN, where the limit of detection and the limit of quantification values were 0.057 and 0.19 nM, respectively. The immunosensor exhibited good reproducibility and specificity. In addition, the developed immunosensor is suitable for multiple anti-SCoV2-rN antibody detections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
353. Dynamics of antibody responses after asymptomatic and mild to moderate SARS-CoV-2 infections: Real-world data in a resource-limited country
- Author
-
Sayabovorn, Naruemit, Phisalprapa, Pochamana, Srivanichakorn, Weerachai, Chaisathaphol, Thanet, Washirasaksiri, Chaiwat, Sitasuwan, Tullaya, Tinmanee, Rungsima, Kositamongkol, Chayanis, Nimitpunya, Pongpol, Mepramoon, Euarat, Ariyakunaphan, Pinyapat, Woradetsittichai, Diana, Chayakulkeeree, Methee, Phoompoung, Pakpoom, Mayurasakorn, Korapat, Sookrung, Nitat, Tungtrongchitr, Anchalee, Wanitphakdeedecha, Rungsima, Muangman, Saipin, Senawong, Sansnee, Tangjittipokin, Watip, Sanpawitayakul, Gornmigar, Nopmaneejumruslers, Cherdchai, Vamvanij, Visit, and Auesomwang, Chonticha
- Published
- 2023
354. Clinical and virological features of SARS-CoV-2 variants during the four waves of the pandemic in the Mexican Southeast
- Author
-
Baeza-Flores, Guadalupe del Carmen, Luna-Arias, Juan Pedro, Ruiz-Quinones, Jesus Arturo, Boldo-Leon, Xavier Miguel, Cedro-Tanda, Alberto, Garnica-Lopez, Dora, Mendoza-Vargas, Alfredo, Magana-Cerino, Jesus M, and Martinez-Lopez, Mirian Carolina
- Published
- 2023
355. Cerebral cryptococcosis associated with CD4+ T-lymphocytopenia in non-HIV patients after SARS-COV-2 infection: Case series in a specialized institute in Lima, Peru
- Author
-
Huamani-Cordova, Juana M, Hueda-Zavaleta, Miguel, Vargas-Bellina, Victor, Simbron-Ribbeck, Lourdes, del Rosario Chong-Chinchay, Katty, de la Torre, Juan C Gomez, and Benites-Zapata, Vicente A
- Published
- 2023
356. Impaired Cardiorespiratory Fitness of Elite Athletes after Asymptomatic or Mild SARS-CoV-2 Infection.
- Author
-
Stojmenović T and Marković S
- Subjects
- Humans, Male, Adult, SARS-CoV-2, Basketball physiology, Young Adult, Asymptomatic Infections, COVID-19 physiopathology, COVID-19 complications, Cardiorespiratory Fitness physiology, Athletes statistics & numerical data, Exercise Test methods, Oxygen Consumption physiology
- Abstract
Background and Objectives: The aim of the study was to evaluate the health status of professional athletes after recovering from COVID-19 and the impact that SARS-CoV-2 had on their overall cardiorespiratory fitness, which was done by conducting cardiopulmonary exercise testing (CPET). Materials and Methods: A total of twenty-seven professional basketball players (Euroleague Basketball and the ABA League) participated in the study. CPET was performed before (as part of their regular preparticipation exam, during the pre-season period), as well as after SARS-CoV-2 infection (after two weeks of home isolation, during the competitive part of the season). CPET was performed on a treadmill, while cardiovascular, respiratory, and metabolic functions were evaluated by using a breath-by-breath analysis technique (Quark CPET system manufactured by Cosmed, Rome, Italy). Results: Maximal oxygen consumption and aerobic efficiency were significantly reduced after SARS-CoV-2 infection ( p = 0.000). An obvious decrease in oxygen pulse was observed during CPET after recovering from COVID-19 ( p = 0.001), as was deterioration of ventilatory efficiency. Internal respiration was the most negatively affected. An early transition from aerobic to anaerobic mechanisms of creating energy for work and intensive metabolic fatigue were obvious after SARS-CoV-2 infection. Conclusions: Although it was believed that SARS-CoV-2 only affects the cardiopulmonary status of the elderly population and people with associated comorbidities, it is clear from this research that professional athletes can also be at certain risk. Even though no pathological cardiovascular and respiratory changes were found in athletes after COVID-19, results showed significantly decreased cardiorespiratory fitness, with an emphasis on internal respiration.
- Published
- 2024
- Full Text
- View/download PDF
357. Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients.
- Author
-
Exquis, Nadia, Dionisi, Benjamin, Samer, Caroline Flora, Rollason, Victoria, Curtin, François, Zekry, Dina, Graf, Christophe, Prendki, Virgnie, and Ing Lorenzini, Kuntheavy
- Subjects
- *
RITONAVIR , *SARS-CoV-2 Omicron variant , *DRUG side effects , *OLDER patients , *SARS-CoV-2 , *ELECTRONIC health records - Abstract
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs. (2) Methods: A retrospective study of electronic health records (EHRs) aiming to describe antiviral (nirmatrelvir and ritonavir (nirmatrelvir/r) or remdesivir) use, drug–drug interactions (DDIs) and adverse drug reactions (ADRs) in elderly patients (75 and over), hospitalized with mild-to-moderate COVID-19 between July 2022 and June 2023. (3) Results: Out of 491 patients (mean age: 86.9 years), 180 (36.7%) received nirmatrelvir/r, 78 (15.9%) received remdesivir, and 233 (47.4%) received no antiviral therapy. No association was found between the choice of antiviral and the demographic or medical data. No serious ADR was observed. Nirmatrelvir/r dosage adjustment was inadequate in 65% of patients with renal impairment. In total, 128 patients (71%) on nirmatrelvir/r had potential pharmacokinetic DDIs, with 43 resulting in a possibly related ADR. In the remdesivir group, pharmacodynamic DDIs were more frequent, with QTc prolongation risk in 56 patients (72%). Only 20 patients underwent follow-up ECG, revealing QTc prolongation in 4. (4) Conclusions: There is an underutilization of antivirals despite their justified indications. Nirmatrelvir/r dosage was rarely adjusted to renal function. Dose adjustments and closer monitoring are needed due to the high risk of drug interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
358. Special Issue "Advances in Antiviral Agents against SARS-CoV-2 and Its Variants".
- Author
-
Esposito F and Cannalire R
- Subjects
- Humans, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, SARS-CoV-2, COVID-19
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with 770 million reported cases and around 7 million deaths, represents the worst pandemic in the last 100 years [...].
- Published
- 2023
- Full Text
- View/download PDF
359. The Complex Proteolipidic Behavior of the SARS-CoV-2 Envelope Protein Channel: Weak Selectivity and Heterogeneous Oligomerization.
- Author
-
Surya W, Tavares-Neto E, Sanchis A, Queralt-Martín M, Alcaraz A, Torres J, and Aguilella VM
- Subjects
- Humans, Viral Envelope Proteins chemistry, Calcium, Pandemics, Ions, Lipids, SARS-CoV-2 metabolism, COVID-19
- Abstract
The envelope (E) protein is a small polypeptide that can form ion channels in coronaviruses. In SARS coronavirus 2 (SARS-CoV-2), the agent that caused the recent COVID-19 pandemic, and its predecessor SARS-CoV-1, E protein is found in the endoplasmic reticulum-Golgi intermediate compartment (ERGIC), where virion budding takes place. Several reports claim that E protein promotes the formation of "cation-selective channels". However, whether this term represents specificity to certain ions (e.g., potassium or calcium) or the partial or total exclusion of anions is debatable. Herein, we discuss this claim based on the available data for SARS-CoV-1 and -2 E and on new experiments performed using the untagged full-length E protein from SARS-CoV-2 in planar lipid membranes of different types, including those that closely mimic the ERGIC membrane composition. We provide evidence that the selectivity of the E-induced channels is very mild and depends strongly on lipid environment. Thus, despite past and recent claims, we found no indication that the E protein forms cation-selective channels that prevent anion transport, and even less that E protein forms bona fide specific calcium channels. In fact, the E channel maintains its multi-ionic non-specific neutral character even in concentrated solutions of Ca
2+ ions. Also, in contrast to previous studies, we found no evidence that SARS-CoV-2 E channel activation requires a particular voltage, high calcium concentrations or low pH, in agreement with available data from SARS-CoV-1 E. In addition, sedimentation velocity experiments suggest that the E channel population is mostly pentameric, but very dynamic and probably heterogeneous, consistent with the broad distribution of conductance values typically found in electrophysiological experiments. The latter has been explained by the presence of proteolipidic channel structures.- Published
- 2023
- Full Text
- View/download PDF
360. SARS-CoV-2 Omicron Specific Mutations Affecting Infectivity, Fusogenicity, and Partial TMPRSS2-Independency.
- Author
-
Strobelt R, Broennimann K, Adler J, and Shaul Y
- Subjects
- Humans, Pandemics, Mutation, Spike Glycoprotein, Coronavirus genetics, Serine Endopeptidases genetics, SARS-CoV-2 genetics, COVID-19
- Abstract
The COVID-19 pandemic resulted from the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since its first appearance in 2019, new SARS-CoV-2 variants of concern (VOCs) have emerged frequently, changing the infection's dynamic. SARS-CoV-2 infects cells via two distinct entry routes; receptor-mediated endocytosis or membrane fusion, depending on the absence or presence of transmembrane serine protease 2 (TMPRSS2), respectively. In laboratory conditions, the Omicron SARS-CoV-2 strain inefficiently infects cells predominantly via endocytosis and is phenotypically characterized by decreased syncytia formation compared to the earlier Delta variant. Thus, it is important to characterize Omicron's unique mutations and their phenotypic manifestations. Here, by utilizing SARS-CoV-2 pseudovirions, we report that the specific Omicron Spike F375 residue decreases infectivity, and its conversion to the Delta S375 sequence significantly increases Omicron infectivity. Further, we identified that residue Y655 decreases Omicron's TMPRSS2 dependency and entry via membrane fusion. The Y655H, K764N, K856N and K969N Omicron revertant mutations, bearing the Delta variant sequence, increased the cytopathic effect of cell-cell fusion, suggesting these Omicron-specific residues reduced the severity of SARS-CoV-2. This study of the correlation of the mutational profile with the phenotypic outcome should sensitize our alertness towards emerging VOCs.
- Published
- 2023
- Full Text
- View/download PDF
361. SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.
- Author
-
Antia, Avan, Alvarado, David M., Zeng, Qiru, Casorla-Perez, Luis A., Davis, Deanna L., Sonnek, Naomi M., Ciorba, Matthew A., and Ding, Siyuan
- Subjects
- *
SARS-CoV-2 Omicron variant , *SARS-CoV-2 Delta variant , *EPITHELIAL cells , *POST-acute COVID-19 syndrome , *LUNGS , *DIGESTIVE system diseases - Abstract
The Omicron variant of SARS-CoV-2, characterized by multiple subvariants including BA.1, XBB.1.5, EG.5, and JN.1, became the predominant strain in early 2022. Studies indicate that Omicron replicates less efficiently in lung tissue compared to the ancestral strain. However, the infectivity of Omicron in the gastrointestinal tract is not fully defined, despite the fact that 70% of COVID-19 patients experience digestive disease symptoms. Here, using primary human colonoids, we found that, regardless of individual variability, Omicron infects colon cells similarly or less effectively than the ancestral strain or the Delta variant. The variant induced limited type III interferon expression and showed no significant impact on epithelial integrity. Further experiments revealed inefficient cell-to-cell spread and spike protein cleavage in the Omicron spike protein, possibly contributing to its lower infectious particle levels. The findings highlight the variant-specific replication differences in human colonoids, providing insights into the enteric tropism of Omicron and its relevance to long COVID symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
362. The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome.
- Author
-
Sanduzzi Zamparelli, Stefano, Fucci, Vincenzo, Rea, Gaetano, Perna, Francesco, Bocchino, Marialuisa, and Sanduzzi Zamparelli, Alessandro
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *COVID-19 pandemic , *ANTIGENS , *PNEUMONIA , *VON Willebrand disease - Abstract
Background: The COVID-19 pandemic caused by SARS-CoV-2 continues to pose a significant threat worldwide, with severe cases leading to hospitalization and death. This study aims to evaluate the potential use of serum nucleocapsid antigen (NAg) and Krebs von den Lungen-6 glycoprotein (KL-6) as biomarkers of severe COVID-19 and to investigate their correlation with clinical, radiological, and biochemical parameters. Methods: This retrospective study included 128 patients with confirmed SARS-CoV-2 infection admitted to a Neapolitan hospital in Italy between October 2020 and July 2021. Demographic, clinical, and laboratory data were collected, including serum levels of NAg and KL-6. The Chung et al. Computed Tomography Severity Score (TSS) was used to assess the severity of pneumonia, and outcomes were classified as home discharge, rehabilitation, and death. Statistical analyses were performed to compare Group I (home discharge and rehabilitation) and Group II (death, sub-intensive care, and ICU stay) based on demographic data, laboratory parameters, and TSS. Results: Group II patients showed worse outcomes with higher levels of NAg, KL-6, and inflammatory markers, including interleukin-6 (IL-6), interleukin-2 receptor (IL-2R), and adrenomedullin. TSS was also significantly higher in Group II, with a positive correlation between TSS and NAg and KL-6 levels. Group I patients had higher values of hemoglobin (Hb) and platelets (PLT), while Group II patients had higher values of C-reactive protein (CRP), procalcitonin (PCT), D-Dimer, and glycemia. No significant difference was observed in gender distribution. Conclusions: Serum NAg and KL-6 levels are potential biomarkers of severe COVID-19 pneumonia, with higher levels indicating greater inflammation and organ damage. NAg may help identify infected patients at an increased risk of severe COVID-19 and ensure their admission to the most appropriate level of care. KL-6 may help predict interstitial lung damage and the severity of clinical features. Further studies are needed to establish a decision-making cut-off for these biomarkers in COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
363. Asymptomatic and mild SARS-CoV-2 infections in a hungarian outpatient cohort in the first year of the covid-19 pandemic
- Author
-
Jankovics, Istvan, Muller, Cecília, Gonczol, Eva, Visontai, Ildiko, Varga, Istvan, Lorincz, Marta, Kuti, David, Hasitz, Agnes, Malik, Peter, Ursu, Krisztina, Banyasz, Borbala, Sarkadi, Julia, and Denes, Bela
- Published
- 2023
364. SARS-CoV-2 Post-Infection and Sepsis by 'Saccharomyces cerevisiae': A fatal case report - focus on fungal susceptibility and potential virulence attributes
- Author
-
Ramos, Livia S, Mokus, Luca, Frota, Heloisa F, Santos, Marcos V, Oliveira, Simone SC, Oliveira, Manoel ME, Costa, Gisela L, Alves, Ana Luisa, Bernardes-Engemann, Andrea R, Orofino-Costa, Rosane, Aor, Ana Carolina, Branquinha, Marta H, and Santos, Andre LS
- Published
- 2023
365. Development of a Fluorescent Assay and Imidazole-Containing Inhibitors by Targeting SARS-CoV-2 Nsp13 Helicase.
- Author
-
Zhang, Chuang, Yu, Junhui, Deng, Mingzhenlong, Zhang, Qingqing, Jin, Fei, Chen, Lei, Li, Yan, and He, Bin
- Subjects
- *
SARS-CoV-2 , *LIFE cycles (Biology) , *SUBSTITUTION reactions , *DNA helicases , *CORONAVIRUSES , *HIGH throughput screening (Drug development) , *IMIDAZOLES - Abstract
Nsp13, a non-structural protein belonging to the coronavirus family 1B (SF1B) helicase, exhibits 5′–3′ polarity-dependent DNA or RNA unwinding using NTPs. Crucially, it serves as a key component of the viral replication–transcription complex (RTC), playing an indispensable role in the coronavirus life cycle and thereby making it a promising target for broad-spectrum antiviral therapies. The imidazole scaffold, known for its antiviral potential, has been proposed as a potential scaffold. In this study, a fluorescence-based assay was designed by labeling dsDNA substrates with a commercial fluorophore and monitoring signal changes upon Nsp13 helicase activity. Optimization and high-throughput screening validated the feasibility of this approach. In accordance with the structural characteristics of ADP, we employed a structural-based design strategy to synthesize three classes of imidazole-based compounds through substitution reaction. Through in vitro activity research, pharmacokinetic parameter analysis, and molecular docking simulation, we identified compounds A16 (IC50 = 1.25 μM) and B3 (IC50 = 0.98 μM) as potential lead antiviral compounds for further targeted drug research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
366. Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein.
- Author
-
Liang T, Xiao S, Wu Z, Lv X, Liu S, Hu M, Li G, Li P, and Ma X
- Subjects
- Humans, Phenothiazines pharmacology, Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19
- Abstract
Novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and continues to threaten humanity due to the persistent emergence of new variants. Therefore, developing more effective and broad-spectrum therapeutic and prophylactic drugs against infection by SARS-CoV-2 and its variants, as well as future emerging CoVs, is urgently needed. In this study, we screened several US FDA-approved drugs and identified phenothiazine derivatives with the ability to potently inhibit the infection of pseudotyped SARS-CoV-2 and distinct variants of concern (VOCs), including B.1.617.2 (Delta) and currently circulating Omicron sublineages XBB and BQ.1.1, as well as pseudotyped SARS-CoV and MERS-CoV. Mechanistic studies suggested that phenothiazines predominantly inhibited SARS-CoV-2 pseudovirus (PsV) infection at the early stage and potentially bound to the spike (S) protein of SARS-CoV-2, which may prevent the proteolytic cleavage of the S protein, thereby exhibiting inhibitory activity against SARS-CoV-2 infection. In summary, our findings suggest that phenothiazines can serve as a potential broad-spectrum therapeutic drug for the treatment of SARS-CoV-2 infection as well as the infection of future emerging human coronaviruses (HCoVs).
- Published
- 2023
- Full Text
- View/download PDF
367. SARS-CoV-2 Spike Protein Interaction Space.
- Author
-
Lungu CN and Putz MV
- Subjects
- Humans, Spike Glycoprotein, Coronavirus metabolism, Angiotensin-Converting Enzyme 2 metabolism, Receptors, Virus metabolism, Protein Binding, Ligands, Peptidyl-Dipeptidase A metabolism, SARS-CoV-2 metabolism, COVID-19
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a +sense single-strand RNA virus. The virus has four major surface proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), respectively. The constitutive proteins present a high grade of symmetry. Identifying a binding site is difficult. The virion is approximately 50-200 nm in diameter. Angiotensin-converting enzyme 2 (ACE2) acts as the cell receptor for the virus. SARS-CoV-2 has an increased affinity to human ACE2 compared with the original SAR strain. Topological space, and its symmetry, is a critical component in molecular interactions. By exploring this space, a suitable ligand space can be characterized accordingly. A spike protein (S) computational model in a complex with ACE 2 was generated using silica methods. Topological spaces were probed using high computational throughput screening techniques to identify and characterize the topological space of both SARS and SARS-CoV-2 spike protein and its ligand space. In order to identify the symmetry clusters, computational analysis techniques, together with statistical analysis, were utilized. The computations are based on crystallographic protein data bank PDB-based models of constitutive proteins. Cartesian coordinates of component atoms and some cluster maps were generated and analyzed. Dihedral angles were used in order to compute a topological receptor space. This computational study uses a multimodal representation of spike protein interactions with some fragment proteins. The chemical space of the receptors (a dimensional volume) suggests the relevance of the receptor as a drug target. The spike protein S of SARS and SARS-CoV-2 is analyzed and compared. The results suggest a mirror symmetry of SARS and SARS-CoV-2 spike proteins. The results show thatSARS-CoV-2 space is variable and has a distinct topology. In conclusion, surface proteins grant virion variability and symmetry in interactions with a potential complementary target (protein, antibody, ligand). The mirror symmetry of dihedral angle clusters determines a high specificity of the receptor space.
- Published
- 2023
- Full Text
- View/download PDF
368. Insights into the SARS-CoV-2 ORF6 Mechanism of Action.
- Author
-
Krachmarova E, Petkov P, Lilkova E, Ilieva N, Rangelov M, Todorova N, Malinova K, Hristova R, Nacheva G, Gospodinov A, and Litov L
- Subjects
- Humans, Active Transport, Cell Nucleus, Cytoplasm, COVID-19 genetics, COVID-19 metabolism, SARS-CoV-2 genetics, SARS-CoV-2 metabolism, SARS-CoV-2 pathogenicity
- Abstract
ORF6 is responsible for suppressing the immune response of cells infected by the SARS-CoV-2 virus. It is also the most toxic protein of SARS-CoV-2, and its actions are associated with the viral pathogenicity. Here, we study in silico and in vitro the structure of the protein, its interaction with RAE1 and the mechanism of action behind its high toxicity. We show both computationally and experimentally that SARS-CoV-2 ORF6, embedded in the cytoplasmic membranes, binds to RAE1 and sequesters it in the cytoplasm, thus depleting its availability in the nucleus and impairing nucleocytoplasmic mRNA transport. This negatively affects the cellular genome stability by compromising the cell cycle progression into the S-phase and by promoting the accumulation of RNA-DNA hybrids. Understanding the multiple ways in which ORF6 affects DNA replication may also have important implications for elucidating the pathogenicity of SARS-CoV-2 and developing therapeutic strategies to mitigate its deleterious effects on host cells.
- Published
- 2023
- Full Text
- View/download PDF
369. An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement.
- Author
-
Rocha VPC, Quadros HC, Fernandes AMS, Gonçalves LP, Badaró RJDS, Soares MBP, and Machado BAS
- Subjects
- Humans, Antibodies, Neutralizing, Antibodies, Viral, Peptidyl-Dipeptidase A metabolism, Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19
- Abstract
SARS-CoV-2 is the etiological agent of the coronavirus disease-19 (COVID-19) and is responsible for the pandemic that started in 2020. The virus enters the host cell through the interaction of its spike glycoprotein with the angiotensin converting enzyme-2 (ACE2) on the host cell's surface. Antibodies present an important role during the infection and pathogenesis due to many reasons, including the neutralization of viruses by binding to different spike epitopes. Therefore, measuring the neutralizing antibody titers in the whole population is important for COVID-19's epidemiology. Different methods are described in the literature, and some have been used to validate the main vaccines used worldwide. In this review, we discuss the main methods used to quantify neutralizing antibody titers, their advantages and limitations, as well as new approaches to determineACE2/spike blockage by antibodies.
- Published
- 2023
- Full Text
- View/download PDF
370. Tumor Necrosis Factor and Interleukin-1β Upregulate NRP2 Expression and Promote SARS-CoV-2 Proliferation.
- Author
-
Ishitoku M, Mokuda S, Araki K, Watanabe H, Kohno H, Sugimoto T, Yoshida Y, Sakaguchi T, Masumoto J, Hirata S, and Sugiyama E
- Subjects
- Humans, Cell Proliferation, Cytokines, Interleukin-1beta, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus metabolism, Tumor Necrosis Factor-alpha pharmacology, COVID-19, SARS-CoV-2 metabolism
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), utilizes the host receptor angiotensin-converting enzyme 2 (ACE2) and the auxiliary receptor Neuropilin-1 (NRP1) to enter host cells. NRP1 has another isoform, NRP2, whose function in COVID-19 has seldom been reported. In addition, although patients with severe cases of COVID-19 often exhibit increased levels of proinflammatory cytokines, the relationship between these cytokines and SARS-CoV-2 proliferation remains unknown. The aim of this study is to clarify the roles of proinflammatory cytokines in Neuropilin expressions and in SARS-CoV-2 infection. To identify the expression patterns of NRP under inflamed and noninflamed conditions, next-generation sequencing (RNA-seq), immunohistochemistry, quantitative real-time PCR, and Western blotting were performed using primary cultured fibroblast-like synoviocytes, MH7A (immortalized cell line of human rheumatoid fibroblast-like synoviocytes), immortalized MRC5 (human embryonic lung fibroblast), and synovial tissues. To measure viral proliferative capacity, SARS-CoV-2 infection experiments were also performed. NRP2 was upregulated in inflamed tissues. Cytokine-stimulated human fibroblast cell lines, such as MH7A and immortalized MRC5, revealed that NRP2 expression increased with co-stimulation of tumor necrosis factor α (TNFα) and interleukin-1 beta (IL-1β) and was suppressed with anti-TNFα antibody alone. TNFα and IL-1β promoted SARS-CoV-2 proliferation and Spike protein binding. The viral proliferation coincided with the expression of NRP2, which was modulated through plasmid transfections. Our results revealed that proinflammatory cytokines, including TNFα, contribute to NRP2 upregulation and SARS-CoV-2 proliferation in host human cells.
- Published
- 2023
- Full Text
- View/download PDF
371. Wastewater-Based Epidemiology to Describe the Evolution of SARS-CoV-2 in the South-East of Spain, and Application of Phylogenetic Analysis and a Machine Learning Approach.
- Author
-
Férez JA, Cuevas-Ferrando E, Ayala-San Nicolás M, Simón Andreu PJ, López R, Truchado P, Sánchez G, and Allende A
- Subjects
- Humans, Phylogeny, Spain epidemiology, Wastewater-Based Epidemiological Monitoring, Pandemics, Wastewater, Machine Learning, SARS-CoV-2 genetics, COVID-19 epidemiology
- Abstract
The COVID-19 pandemic has posed a significant global threat, leading to several initiatives for its control and management. One such initiative involves wastewater-based epidemiology, which has gained attention for its potential to provide early warning of virus outbreaks and real-time information on its spread. In this study, wastewater samples from two wastewater treatment plants (WWTPs) located in the southeast of Spain (region of Murcia), namely Murcia, and Cartagena, were analyzed using RT-qPCR and high-throughput sequencing techniques to describe the evolution of SARS-CoV-2 in the South-East of Spain. Additionally, phylogenetic analysis and machine learning approaches were applied to develop a pre-screening tool for the identification of differences among the variant composition of different wastewater samples. The results confirmed that the levels of SARS-CoV-2 in these wastewater samples changed concerning the number of SARS-CoV-2 cases detected in the population, and variant occurrences were in line with clinical reported data. The sequence analyses helped to describe how the different SARS-CoV-2 variants have been replaced over time. Additionally, the phylogenetic analysis showed that samples obtained at close sampling times exhibited a higher similarity than those obtained more distantly in time. A second analysis using a machine learning approach based on the mutations found in the SARS-CoV-2 spike protein was also conducted. Hierarchical clustering (HC) was used as an efficient unsupervised approach for data analysis. Results indicated that samples obtained in October 2022 in Murcia and Cartagena were significantly different, which corresponded well with the different virus variants circulating in the two locations. The proposed methods in this study are adequate for comparing consensus sequence types of the SARS-CoV-2 sequences as a preliminary evaluation of potential changes in the variants that are circulating in a given population at a specific time point.
- Published
- 2023
- Full Text
- View/download PDF
372. In Silico Substrate-Binding Profiling for SARS-CoV-2 Main Protease (M pro ) Using Hexapeptide Substrates.
- Author
-
Zabo S and Lobb KA
- Subjects
- Humans, Molecular Docking Simulation, Protease Inhibitors chemistry, Cysteine Endopeptidases metabolism, Molecular Dynamics Simulation, Antiviral Agents pharmacology, SARS-CoV-2 metabolism, COVID-19
- Abstract
The SARS-CoV-2 main protease (M
pro ) is essential for the life cycle of the COVID-19 virus. It cleaves the two polyproteins at 11 positions to generate mature proteins for virion formation. The cleavage site on these polyproteins is known to be Leu-Gln↓(Ser/Ala/Gly). A range of hexapeptides that follow the known sequence for recognition and cleavage was constructed using RDKit libraries and complexed with the crystal structure of Mpro (PDB ID 6XHM) through extensive molecular docking calculations. A subset of 131 of these complexes underwent 20 ns molecular dynamics simulations. The analyses of the trajectories from molecular dynamics included principal component analysis (PCA), and a method to compare PCA plots from separate trajectories was developed in terms of encoding PCA progression during the simulations. The hexapeptides formed stable complexes as expected, with reproducible molecular docking of the substrates given the extensiveness of the procedure. Only Lys-Leu-Gln*** (KLQ***) sequence complexes were studied for molecular dynamics. In this subset of complexes, the PCA analysis identified four classifications of protein motions across these sequences. KLQ*** complexes illustrated the effect of changes in substrate on the active site, with implications for understanding the substrate recognition of Mpro and informing the development of small molecule inhibitors.- Published
- 2023
- Full Text
- View/download PDF
373. A New Method to Detect Variants of SARS-CoV-2 Using Reverse Transcription Loop-Mediated Isothermal Amplification Combined with a Bioluminescent Assay in Real Time (RT-LAMP-BART).
- Author
-
Iijima T, Sakai J, Kanamori D, Ando S, Nomura T, Tisi L, Kilgore PE, Percy N, Kohase H, Hayakawa S, Maesaki S, Hoshino T, and Seki M
- Subjects
- Humans, Reverse Transcription genetics, Sensitivity and Specificity, Molecular Diagnostic Techniques methods, Nucleic Acid Amplification Techniques methods, RNA, Luminescent Measurements, RNA, Viral genetics, SARS-CoV-2 genetics, COVID-19 diagnosis, COVID-19 genetics
- Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), of which there are several variants. The three major variants (Alpha, Delta, and Omicron) carry the N501Y, L452R, and Q493R/Q498R mutations, respectively, in the S gene. Control of COVID-19 requires rapid and reliable detection of not only SARS-CoV-2 but also its variants. We previously developed a reverse transcription loop-mediated isothermal amplification assay combined with a bioluminescent assay in real time (RT-LAMP-BART) to detect the L452R mutation in the SARS-CoV-2 spike protein. In this study, we established LAMP primers and peptide nucleic acid probes to detect N501Y and Q493R/Q498R. The LAMP primer sets and PNA probes were designed for the N501Y and Q493R/Q498R mutations on the S gene of SARS-CoV-2. The specificities of RT-LAMP-BART assays were evaluated using five viral and four bacterial reference strains. The sensitivities of RT-LAMP-BART assays were evaluated using synthetic RNAs that included the target sequences, together with RNA-spiked clinical nasopharyngeal and salivary specimens. The results were compared with those of conventional real-time reverse transcription-polymerase chain reaction (RT-PCR) methods. The method correctly identified N501Y and Q493R/Q498R. Within 30 min, the RT-LAMP-BART assays detected up to 100-200 copies of the target genes; conventional real-time RT-PCR required 130 min and detected up to 500-3000 copies. Surprisingly, the real-time RT-PCR for N501Y did not detect the BA.1 and BA.2 variants (Omicron) that exhibited the N501Y mutation. The novel RT-LAMP-BART assay is highly specific and more sensitive than conventional real-time RT-PCR. The new assay is simple, inexpensive, and rapid; thus, it can be useful in efforts to identify SARS-CoV-2 variants of concern.
- Published
- 2023
- Full Text
- View/download PDF
374. In Vitro Analysis of the Effect of SARS-CoV-2 Non-VOC and four Variants of Concern on MHC-Class-I Expression on Calu-3 and Caco-2 Cells.
- Author
-
Bahlmann NA, Mautner L, Hoyos M, Sallard E, Berger C, Dangel A, Jönsson F, Fischer JC, Kreppel F, Zhang W, Esposito I, Bölke E, Baiker A, and Ehrhardt A
- Subjects
- Adult, Humans, Caco-2 Cells, Spike Glycoprotein, Coronavirus genetics, Immunoglobulin G, SARS-CoV-2, COVID-19 genetics
- Abstract
As the MHC-I-pathway is key to antigen presentation to cytotoxic T-cells and, therefore, recognition by the host adaptive immune system, we hypothesized that SARS-CoV-2 including its Variants of Concern (VOCs), influences MHC-I expression on epithelial cell surfaces as an immune evasion strategy. We conducted an in vitro time course experiment with the human airway epithelial cell line Calu-3 and the human colorectal adenocarcinoma cell line Caco-2. Cells were infected with SARS-CoV-2 strains non-VOC/B.1.1, Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1, and Delta/B.1.617.2. At 2, 24, 48 and 72 h post-infection we performed RT-qPCR to track viral replication. Simultaneously, we performed intracellular staining with a serum of a double-vaccinated healthy adult containing a high amount of spike protein antibody. In flow cytometry experiments, we differentiated between infected (spike protein positive) and bystander (spike protein negative) cells. To compare their HLA expression levels, cells were stained extracellularly with anti-HLA-A-IgG and anti-HLA-B,C-IgG. While HLA-A expression was stable on infected Calu-3 cells for all variants, it increased to different degrees on bystander cells in samples infected with VOCs Beta, Gamma, Delta, or non-VOC over the time course analyzed. In contrast, HLA-A levels were stable in bystander Calu-3 cells in samples infected with the Alpha variant. The upregulation of MHC-I on spike protein negative bystander cells in Calu-3 cell cultures infected with Beta, Gamma, Delta, and partly non-VOC might suggest that infected cells are still capable of secreting inflammatory cytokines like type-I interferons stimulating the MHC-I expression on bystander cells. In comparison, there was no distinct effect on HLA expression level on Caco-2 cells of any of the VOCs or non-VOC. Further investigations of the full range of immune evasion strategies of SARS-CoV-2 variants are warranted.
- Published
- 2023
- Full Text
- View/download PDF
375. Improving Soluble Expression of SARS-CoV-2 Spike Priming Protease TMPRSS2 with an Artificial Fusing Protein.
- Author
-
Ye X, Ling X, Wu M, Bai G, Yuan M, and Rao L
- Subjects
- Animals, Peptide Hydrolases metabolism, Spike Glycoprotein, Coronavirus metabolism, Proteolysis, Virus Internalization, Mammals metabolism, SARS-CoV-2 metabolism, COVID-19
- Abstract
SARS-CoV-2 relies on the recognition of the spike protein by the host cell receptor ACE2 for cellular entry. In this process, transmembrane serine protease 2 (TMPRSS2) plays a pivotal role, as it acts as the principal priming agent catalyzing spike protein cleavage to initiate the fusion of the cell membrane with the virus. Thus, TMPRSS2 is an ideal pharmacological target for COVID-19 therapy development, and the effective production of high-quality TMPRSS2 protein is essential for basic and pharmacological research. Unfortunately, as a mammalian-originated protein, TMPRSS2 could not be solubly expressed in the prokaryotic system. In this study, we applied different protein engineering methods and found that an artificial protein XXA derived from an antifreeze protein can effectively promote the proper folding of TMPRSS2, leading to a significant improvement in the yield of its soluble form. Our study also showed that the fused XXA protein did not influence the enzymatic catalytic activity; instead, it greatly enhanced TMPRSS2's thermostability. Therefore, our strategy for increasing TMPRSS2 expression would be beneficial for the large-scale production of this stable enzyme, which would accelerate aniti-SARS-CoV-2 therapeutics development.
- Published
- 2023
- Full Text
- View/download PDF
376. CoVigator-A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants.
- Author
-
Bukur T, Riesgo-Ferreiro P, Sorn P, Gudimella R, Hausmann J, Rösler T, Löwer M, Schrörs B, and Sahin U
- Subjects
- Humans, COVID-19 Vaccines, Pandemics, Genomics, Knowledge Bases, Mutation, Spike Glycoprotein, Coronavirus, SARS-CoV-2 genetics, COVID-19 epidemiology
- Abstract
Background: The outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) resulted in the global COVID-19 pandemic. The urgency for an effective SARS-CoV-2 vaccine has led to the development of the first series of vaccines at unprecedented speed. The discovery of SARS-CoV-2 spike-glycoprotein mutants, however, and consequentially the potential to escape vaccine-induced protection and increased infectivity, demonstrates the persisting importance of monitoring SARS-CoV-2 mutations to enable early detection and tracking of genomic variants of concern., Results: We developed the CoVigator tool with three components: (1) a knowledge base that collects new SARS-CoV-2 genomic data, processes it and stores its results; (2) a comprehensive variant calling pipeline; (3) an interactive dashboard highlighting the most relevant findings. The knowledge base routinely downloads and processes virus genome assemblies or raw sequencing data from the COVID-19 Data Portal (C19DP) and the European Nucleotide Archive (ENA), respectively. The results of variant calling are visualized through the dashboard in the form of tables and customizable graphs, making it a versatile tool for tracking SARS-CoV-2 variants. We put a special emphasis on the identification of intrahost mutations and make available to the community what is, to the best of our knowledge, the largest dataset on SARS-CoV-2 intrahost mutations. In the spirit of open data, all CoVigator results are available for download. The CoVigator dashboard is accessible via covigator.tron-mainz.de., Conclusions: With increasing demand worldwide in genome surveillance for tracking the spread of SARS-CoV-2, CoVigator will be a valuable resource of an up-to-date list of mutations, which can be incorporated into global efforts.
- Published
- 2023
- Full Text
- View/download PDF
377. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2.
- Author
-
Subhadra B, Agrawal R, Pal VK, Chenine AL, Mattathil JG, and Singh A
- Subjects
- Chlorocebus aethiops, Animals, Humans, Tandem Mass Spectrometry, Vero Cells, Antiviral Agents pharmacology, Vesiculovirus, Spike Glycoprotein, Coronavirus genetics, SARS-CoV-2 genetics, COVID-19
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected 762 million people with over 6.9 million deaths worldwide. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severities, are still an unmet global medical need. We studied Bi121, which is a standardized polyphenolic-rich compound isolated from Pelargonium sidoides , against recombinant vesicular stomatitis virus (rVSV)-pseudotyped SARS-CoV-2S (mutations in the spike protein) of six different variants of SARS-CoV-2. Bi121 was effective at neutralizing all six rVSV-ΔG-SARS-CoV-2S variants. The antiviral activity of Bi121 was also assessed against SARS-CoV-2 variants (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta), and Omicron) in Vero cells and HEK-ACE2 cell lines using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity against all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity. Bi121 fractions generated using HPLC showed antiviral activity in three fractions out of eight against SARS-CoV-2. The dominant compound identified in all three fractions using LC/MS/MS analysis was Neoilludin B. In silico structural modeling studies with Neoilludin B showed that it has a novel RNA-intercalating activity toward RNA viruses. In silico findings and the antiviral activity of this compound against several SARS-CoV-2 variants support further evaluation as a potential treatment of COVID-19.
- Published
- 2023
- Full Text
- View/download PDF
378. Molecular Epidemiology of SARS-CoV-2 during Five COVID-19 Waves and the Significance of Low-Frequency Lineages.
- Author
-
Subramoney K, Mtileni N, Giandhari J, Naidoo Y, Ramphal Y, Pillay S, Ramphal U, Maharaj A, Tshiabuila D, Tegally H, Wilkinson E, de Oliveira T, Fielding BC, and Treurnicht FK
- Subjects
- Humans, Animals, Molecular Epidemiology, Databases, Factual, Drug Resistance, Viral, Mutation, Pangolins, Spike Glycoprotein, Coronavirus, SARS-CoV-2 genetics, COVID-19 epidemiology
- Abstract
SARS-CoV-2 lineages and variants of concern (VOC) have gained more efficient transmission and immune evasion properties with time. We describe the circulation of VOCs in South Africa and the potential role of low-frequency lineages on the emergence of future lineages. Whole genome sequencing was performed on SARS-CoV-2 samples from South Africa. Sequences were analysed with Nextstrain pangolin tools and Stanford University Coronavirus Antiviral & Resistance Database. In 2020, 24 lineages were detected, with B.1 (3%; 8/278), B.1.1 (16%; 45/278), B.1.1.348 (3%; 8/278), B.1.1.52 (5%; 13/278), C.1 (13%; 37/278) and C.2 (2%; 6/278) circulating during the first wave. Beta emerged late in 2020, dominating the second wave of infection. B.1 and B.1.1 continued to circulate at low frequencies in 2021 and B.1.1 re-emerged in 2022. Beta was outcompeted by Delta in 2021, which was thereafter outcompeted by Omicron sub-lineages during the 4th and 5th waves in 2022. Several significant mutations identified in VOCs were also detected in low-frequency lineages, including S68F (E protein); I82T (M protein); P13L, R203K and G204R/K (N protein); R126S (ORF3a); P323L (RdRp); and N501Y, E484K, D614G, H655Y and N679K (S protein). Low-frequency variants, together with VOCs circulating, may lead to convergence and the emergence of future lineages that may increase transmissibility, infectivity and escape vaccine-induced or natural host immunity.
- Published
- 2023
- Full Text
- View/download PDF
379. Quantitative Mutation Analysis of Genes and Proteins of Major SARS-CoV-2 Variants of Concern and Interest.
- Author
-
Liang F
- Subjects
- Humans, Antigens, Viral, Mutation, Spike Glycoprotein, Coronavirus genetics, SARS-CoV-2 genetics, COVID-19
- Abstract
Of various SARS-CoV-2 variants, some have drawn special concern or interest because of their heightened disease threat. The mutability of individual SARS-CoV-2 genes/proteins presumably varies. The present study quantified gene/protein mutations in 13 major SARS-CoV-2 variants of concern/interest, and analyzed viral protein antigenicity using bioinformatics. The results from 187 carefully perused genome clones showed significantly higher mean percent mutations in the spike, ORF8, nucleocapsid, and NSP6 than in other viral proteins. The ORF8 and spike proteins also tolerated higher maximal percent mutations. The omicron variant presented more percent mutations in the NSP6 and structural proteins, whereas the delta featured more in the ORF7a. Omicron subvariant BA.2 exhibited more mutations in ORF6, and omicron BA.4 had more in NSP1, ORF6, and ORF7b, relative to omicron BA.1. Delta subvariants AY.4 and AY.5 bore more mutations in ORF7b and ORF8 than delta B.1.617.2. Predicted antigen ratios of SARS-CoV-2 proteins significantly vary (range: 38-88%). To overcome SARS-CoV-2 immune evasion, the relatively conserved, potentially immunogenic NSP4, NSP13, NSP14, membrane, and ORF3a viral proteins may serve as more suitable targets for molecular vaccines or therapeutics than the mutation-prone NSP6, spike, ORF8, or nucleocapsid protein. Further investigation into distinct mutations of the variants/subvariants may help understand SARS-CoV-2 pathogenesis.
- Published
- 2023
- Full Text
- View/download PDF
380. GRP78 Inhibitor YUM70 Suppresses SARS-CoV-2 Viral Entry, Spike Protein Production and Ameliorates Lung Damage.
- Author
-
Ha DP, Shin WJ, Hernandez JC, Neamati N, Dubeau L, Machida K, and Lee AS
- Subjects
- Animals, Mice, Humans, Endoplasmic Reticulum Chaperone BiP, Virus Internalization, Spike Glycoprotein, Coronavirus, Pandemics, Lung, SARS-CoV-2 physiology, COVID-19
- Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has given rise to many new variants with increased transmissibility and the ability to evade vaccine protection. The 78-kDa glucose-regulated protein (GRP78) is a major endoplasmic reticulum (ER) chaperone that has been recently implicated as an essential host factor for SARS-CoV-2 entry and infection. In this study, we investigated the efficacy of YUM70, a small molecule inhibitor of GRP78, to block SARS-CoV-2 viral entry and infection in vitro and in vivo. Using human lung epithelial cells and pseudoviral particles carrying spike proteins from different SARS-CoV-2 variants, we found that YUM70 was equally effective at blocking viral entry mediated by original and variant spike proteins. Furthermore, YUM70 reduced SARS-CoV-2 infection without impacting cell viability in vitro and suppressed viral protein production following SARS-CoV-2 infection. Additionally, YUM70 rescued the cell viability of multi-cellular human lung and liver 3D organoids transfected with a SARS-CoV-2 replicon. Importantly, YUM70 treatment ameliorated lung damage in transgenic mice infected with SARS-CoV-2, which correlated with reduced weight loss and longer survival. Thus, GRP78 inhibition may be a promising approach to augment existing therapies to block SARS-CoV-2, its variants, and other viruses that utilize GRP78 for entry and infection.
- Published
- 2023
- Full Text
- View/download PDF
381. Different In Silico Approaches Using Heterocyclic Derivatives against the Binding between Different Lineages of SARS-CoV-2 and ACE2.
- Author
-
Sipala F, Cavallaro G, Forte G, Satriano C, Giuffrida A, Fraix A, Spadaro A, Petralia S, Bonaccorso C, Fortuna CG, and Ronsisvalle S
- Subjects
- Humans, Spike Glycoprotein, Coronavirus metabolism, Angiotensin-Converting Enzyme 2 metabolism, Protein Binding, SARS-CoV-2 metabolism, COVID-19
- Abstract
Over the last few years, the study of the SARS-CoV-2 spike protein and its mutations has become essential in understanding how it interacts with human host receptors. Since the crystallized structure of the spike protein bound to the angiotensin-converting enzyme 2 (ACE2) receptor was released (PDB code 6M0J), in silico studies have been performed to understand the interactions between these two proteins. Specifically, in this study, heterocyclic compounds with different chemical characteristics were examined to highlight the possibility of interaction with the spike protein and the disruption of the interaction between ACE2 and the spike protein. Our results showed that these compounds interacted with the spike protein and interposed in the interaction zone with ACE2. Although further studies are needed, this work points to these heterocyclic push-pull compounds as possible agents capable of interacting with the spike protein, with the potential for the inhibition of spike protein-ACE2 binding.
- Published
- 2023
- Full Text
- View/download PDF
382. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape
- Author
-
Raisinghani, Nishank, Alshahrani, Mohammed, Gupta, Grace, and Verkhivker, Gennady
- Subjects
- *
SARS-CoV-2 Omicron variant , *ANGIOTENSIN converting enzyme , *RECEPTOR antibodies , *CELL receptors , *SARS-CoV-2 , *FC receptors - Abstract
In this study, we performed a computational study of binding mechanisms for the SARS-CoV-2 spike Omicron XBB lineages with the host cell receptor ACE2 and a panel of diverse class one antibodies. The central objective of this investigation was to examine the molecular factors underlying epistatic couplings among convergent evolution hotspots that enable optimal balancing of ACE2 binding and antibody evasion for Omicron variants BA.1, BA2, BA.3, BA.4/BA.5, BQ.1.1, XBB.1, XBB.1.5, and XBB.1.5 + L455F/F456L. By combining evolutionary analysis, molecular dynamics simulations, and ensemble-based mutational scanning of spike protein residues in complexes with ACE2, we identified structural stability and binding affinity hotspots that are consistent with the results of biochemical studies. In agreement with the results of deep mutational scanning experiments, our quantitative analysis correctly reproduced strong and variant-specific epistatic effects in the XBB.1.5 and BA.2 variants. It was shown that Y453W and F456L mutations can enhance ACE2 binding when coupled with Q493 in XBB.1.5, while these mutations become destabilized when coupled with the R493 position in the BA.2 variant. The results provided a molecular rationale of the epistatic mechanism in Omicron variants, showing a central role of the Q493/R493 hotspot in modulating epistatic couplings between convergent mutational sites L455F and F456L in XBB lineages. The results of mutational scanning and binding analysis of the Omicron XBB spike variants with ACE2 receptors and a panel of class one antibodies provide a quantitative rationale for the experimental evidence that epistatic interactions of the physically proximal binding hotspots Y501, R498, Q493, L455F, and F456L can determine strong ACE2 binding, while convergent mutational sites F456L and F486P are instrumental in mediating broad antibody resistance. The study supports a mechanism in which the impact on ACE2 binding affinity is mediated through a small group of universal binding hotspots, while the effect of immune evasion could be more variant-dependent and modulated by convergent mutational sites in the conformationally adaptable spike regions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
383. Potential of a Bead-Based Multiplex Assay for SARS-CoV-2 Antibody Detection.
- Author
-
Rottmayer, Karla, Schwarze, Mandy, Jassoy, Christian, Hoffmann, Ralf, Loeffler-Wirth, Henry, and Lehmann, Claudia
- Subjects
- *
IMMUNOGLOBULINS , *SARS-CoV-2 , *MULTIPLEXING , *CONVALESCENT plasma , *SERUM , *FREEZE-thaw cycles , *IMMUNE response , *VIRAL antibodies - Abstract
Simple Summary: In this study, a bead-based multiplex assay for the detection of SARS-CoV-2 antibodies was validated in three study arms. Reproducibility was tested on n = 82 samples. In another arm of n = 30 samples, the assay was compared with several other SARS-CoV-2 antibody assays. In addition, the proportion of neutralising antibodies was determined in n = 58 samples. The bead-based multiplex assay is comparable to commercial ELISA/CLIA tests in terms of antibody detection and can be used to simultaneously detect antibodies against five SARS-CoV-2 domains and six other common cold coronaviruses. The bead-based test is sensitive to repeated freeze-thaw cycles and showed a decrease in reactions. With regard to the neutralising activity of RBD antibodies, we can show that the bead-based multiplex test provides the same results as the surrogate test. Serological assays for SARS-CoV-2 play a pivotal role in the definition of whether patients are infected, the understanding of viral epidemiology, the screening of convalescent sera for therapeutic and prophylactic purposes, and in obtaining a better understanding of the immune response towards the virus. The aim of this study was to investigate the performance of a bead-based multiplex assay. This assay allowed for the simultaneous testing of IgG antibodies against SARS-CoV-2 spike, S1, S2, RBD, and nucleocapsid moieties and S1 of seasonal coronaviruses hCoV-22E, hCoV-HKU1, hCoV-NL63, and hCoV-OC43, as well as MERS and SARS-CoV. We compared the bead-based multiplex assay with commercial ELISA tests. We tested the sera of 27 SARS-CoV-2 PCR-positive individuals who were previously tested with different ELISA assays. Additionally, we investigated the reproducibility of the results by means of multiple testing of the same sera. Finally, the results were correlated with neutralising assays. In summary, the concordance of the qualitative results ranged between 78% and 96% depending on the ELISA assay and the specific antigen. Repeated freezing–thawing cycles resulted in reduced mean fluorescence intensity, while the storage period had no influence in this respect. In our test cohort, we detected up to 36% of sera positive for the development of neutralising antibodies, which is in concordance with the bead-based multiplex and IgG ELISA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
384. Detection of SARS-CoV-2 Delta Variant (B.1.617.2) in Domestic Dogs and Zoo Tigers in England and Jersey during 2021.
- Author
-
Seekings, Amanda H., Shipley, Rebecca, Byrne, Alexander M. P., Shukla, Shweta, Golding, Megan, Amaya-Cuesta, Joan, Goharriz, Hooman, Vitores, Ana Gómez, Lean, Fabian Z. X., James, Joe, Núñez, Alejandro, Breed, Alistair, Frost, Andrew, Balzer, Jörg, Brown, Ian H., Brookes, Sharon M., and McElhinney, Lorraine M.
- Subjects
- *
SARS-CoV-2 Delta variant , *SARS-CoV-2 , *TIGERS , *CAPTIVE wild animals , *ZOOS , *FELIDAE , *DOGS - Abstract
Reverse zoonotic transmission events of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described since the start of the pandemic, and the World Organisation for Animal Health (WOAH) designated the detection of SARS-CoV-2 in animals a reportable disease. Eighteen domestic and zoo animals in Great Britain and Jersey were tested by APHA for SARS-CoV-2 during 2020–2023. One domestic cat (Felis catus), three domestic dogs (Canis lupus familiaris), and three Amur tigers (Panthera tigris altaica) from a zoo were confirmed positive during 2020–2021 and reported to the WOAH. All seven positive animals were linked with known SARS-CoV-2 positive human contacts. Characterisation of the SARS-CoV-2 variants by genome sequencing indicated that the cat was infected with an early SARS-CoV-2 lineage. The three dogs and three tigers were infected with the SARS-CoV-2 Delta variant of concern (B.1.617.2). The role of non-human species in the onward transmission and emergence of new variants of SARS-CoV-2 remain poorly defined. Continued surveillance of SARS-CoV-2 in relevant domestic and captive animal species with high levels of human contact is important to monitor transmission at the human−animal interface and to assess their role as potential animal reservoirs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
385. Structure-Based Optimization of One Neutralizing Antibody against SARS-CoV-2 Variants Bearing the L452R Mutation.
- Author
-
Chen, Yamin, Zha, Jialu, Xu, Shiqi, Shao, Jiang, Liu, Xiaoshan, Li, Dianfan, and Zhang, Xiaoming
- Subjects
- *
SARS-CoV-2 , *SARS-CoV-2 Omicron variant , *IMMUNOGLOBULINS , *GENETIC mutation , *MONOCLONAL antibodies - Abstract
Neutralizing antibodies (nAbs) play an important role against SARS-CoV-2 infections. Previously, we have reported one potent receptor binding domain (RBD)-binding nAb Ab08 against the SARS-CoV-2 prototype and a panel of variants, but Ab08 showed much less efficacy against the variants harboring the L452R mutation. To overcome the antibody escape caused by the L452R mutation, we generated several structure-based Ab08 derivatives. One derivative, Ab08-K99E, displayed the mostly enhanced neutralizing potency against the Delta pseudovirus bearing the L452R mutation compared to the Ab08 and other derivatives. Ab08-K99E also showed improved neutralizing effects against the prototype, Omicron BA.1, and Omicron BA.4/5 pseudoviruses. In addition, compared to the original Ab08, Ab08-K99E exhibited high binding properties and affinities to the RBDs of the prototype, Delta, and Omicron BA.4/5 variants. Altogether, our findings report an optimized nAb, Ab08-K99E, against SARS-CoV-2 variants and demonstrate structure-based optimization as an effective way for antibody development against pathogens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
386. Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters.
- Author
-
Yang, Zhi-Hui, Song, Yan-Li, Pei, Jie, Li, Song-Zhuang, Liu, Rui-Lun, Xiong, Yu, Wu, Jie, Liu, Yuan-Lang, Fan, Hui-Fen, Wu, Jia-Hui, Wang, Ze-Jun, Guo, Jing, Meng, Sheng-Li, Chen, Xiao-Qi, Lu, Jia, and Shen, Shuo
- Subjects
- *
SARS-CoV-2 Omicron variant , *HUMORAL immunity , *MEASLES vaccines , *SARS-CoV-2 , *GOLDEN hamster , *COVID-19 - Abstract
As SARS-CoV-2 continues to evolve and COVID-19 cases rapidly increase among children and adults, there is an urgent need for a safe and effective vaccine that can elicit systemic and mucosal humoral immunity to limit the emergence of new variants. Using the Chinese Hu191 measles virus (MeV-hu191) vaccine strain as a backbone, we developed MeV chimeras stably expressing the prefusion forms of either membrane-anchored, full-length spike (rMeV-preFS), or its soluble secreted spike trimers with the help of the SP-D trimerization tag (rMeV-S+SPD) of SARS-CoV-2 Omicron BA.2. The two vaccine candidates were administrated in golden Syrian hamsters through the intranasal or subcutaneous routes to determine the optimal immunization route for challenge. The intranasal delivery of rMeV-S+SPD induced a more robust mucosal IgA antibody response than the subcutaneous route. The mucosal IgA antibody induced by rMeV-preFS through the intranasal routine was slightly higher than the subcutaneous route, but there was no significant difference. The rMeV-preFS vaccine stimulated higher mucosal IgA than the rMeV-S+SPD vaccine through intranasal or subcutaneous administration. In hamsters, intranasal administration of the rMeV-preFS vaccine elicited high levels of NAbs, protecting against the SARS-CoV-2 Omicron BA.2 variant challenge by reducing virus loads and diminishing pathological changes in vaccinated animals. Encouragingly, sera collected from the rMeV-preFS group consistently showed robust and significantly high neutralizing titers against the latest variant XBB.1.16. These data suggest that rMeV-preFS is a highly promising COVID-19 candidate vaccine that has great potential to be developed into bivalent vaccines (MeV/SARS-CoV-2). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
387. Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants.
- Author
-
Zhang, Xuanxuan, Guan, Lidong, Li, Na, Wang, Ying, Li, Lu, Liu, Mingchen, He, Qian, Lu, Jiansheng, Zeng, Haiyuan, Yu, Shan, Guo, Xinyi, Gong, Jiali, Li, Jing, Gao, Fan, Wu, Xing, Chen, Si, Wang, Qian, Wang, Zhongfang, Huang, Weijin, and Mao, Qunying
- Subjects
- *
SARS-CoV-2 , *MONOCLONAL antibodies , *SARS-CoV-2 Omicron variant - Abstract
Neutralizing antibodies (NtAbs) against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are indicators of vaccine efficacy that enable immunity surveillance. However, the rapid mutation of SARS-CoV-2 variants prevents the timely establishment of standards required for effective XBB vaccine evaluation. Therefore, we prepared four candidate standards (No. 11, No. 44, No. 22, and No. 33) using plasma, purified immunoglobulin, and a broad-spectrum neutralizing monoclonal antibody. Collaborative calibration was conducted across nine Chinese laboratories using neutralization methods against 11 strains containing the XBB and BA.2.86 sublineages. This study demonstrated the reduced neutralization potency of the first International Standard antibodies to SARS-CoV-2 variants of concern against XBB variants. No. 44 displayed broad-spectrum neutralizing activity against XBB sublineages, effectively reduced interlaboratory variability for nearly all XBB variants, and effectively minimized the geometric mean titer (GMT) difference between the live and pseudotyped virus. No. 22 showed a broader spectrum and higher neutralizing activity against all strains but failed to reduce interlaboratory variability. Thus, No. 44 was approved as a National Standard for NtAbs against XBB variants, providing a unified NtAb measurement standard for XBB variants for the first time. Moreover, No. 22 was approved as a national reference reagent for NtAbs against SARS-CoV-2, offering a broad-spectrum activity reference for current and potentially emerging variants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
388. Effects of Strain Differences, Humidity Changes, and Saliva Contamination on the Inactivation of SARS-CoV-2 by Ion Irradiation.
- Author
-
Ahmad Wadi, Afifah Fatimah Azzahra, Onomura, Daichi, Funamori, Hirokazu, Khatun, Mst Mahmuda, Okada, Shunpei, Iizasa, Hisashi, and Yoshiyama, Hironori
- Subjects
- *
HUMIDITY , *SARS-CoV-2 , *VIRUS inactivation , *SALIVA , *SARS-CoV-2 Omicron variant , *IRRADIATION , *VIRAL proteins - Abstract
One of the methods to inactivate viruses is to denature viral proteins using released ions. However, there have been no reports detailing the effects of changes in humidity or contamination with body fluids on the inactivation of viruses. This study investigated the effects of humidity changes and saliva contamination on the efficacy of SARS-CoV-2 inactivation with ions using multiple viral strains. Virus solutions with different infectious titers were dropped onto a circular nitrocellulose membrane and irradiated with ions from 10 cm above the membrane. After the irradiation of ions for 60, 90, and 120 min, changes in viral infectious titers were measured. The effect of ions on virus inactivation under different humidity conditions was also examined using virus solutions containing 90% mixtures of saliva collected from 10 people. A decrease in viral infectivity was observed over time for all strains, but ion irradiation further accelerated the decrease in viral infectivity. Ion irradiation can inactivate all viral strains, but at 80% humidity, the effect did not appear until 90 min after irradiation. The presence of saliva protected the virus from drying and maintained infectiousness for a longer period compared with no saliva. In particular, the Omicron strain retained its infectivity titer longer than the other strains. Ion irradiation demonstrated a consistent reduction in the number of infectious viruses when compared to the control across varying levels of humidity and irradiation periods. This underscores the notable effectiveness of irradiation, even when the reduction effect is as modest as 50%, thereby emphasizing its crucial role in mitigating the rapid dissemination of SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
389. Oropharyngeal Microbiome Analysis in Patients with Varying SARS-CoV-2 Infection Severity: A Prospective Cohort Study.
- Author
-
Siasios, Panagiotis, Giosi, Evangelia, Ouranos, Konstantinos, Christoforidi, Maria, Dimopoulou, Ifigenia, Leshi, Enada, Exindari, Maria, Anastassopoulou, Cleo, and Gioula, Georgia
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *LONGITUDINAL method , *COHORT analysis , *HOSPITAL patients - Abstract
Patients with COVID-19 infection have distinct oropharyngeal microbiota composition and diversity metrics according to disease severity. However, these findings are not consistent across the literature. We conducted a multicenter, prospective study in patients with COVID-19 requiring outpatient versus inpatient management to explore the microbial abundance of taxa at the phylum, family, genus, and species level, and we utilized alpha and beta diversity indices to further describe our findings. We collected oropharyngeal washing specimens at the time of study entry, which coincided with the COVID-19 diagnosis, to conduct all analyses. We included 43 patients in the study, of whom 16 were managed as outpatients and 27 required hospitalization. Proteobacteria, Actinobacteria, Bacteroidetes, Saccharibacteria TM7, Fusobacteria, and Spirochaetes were the most abundant phyla among patients, while 61 different families were detected, of which the Streptococcaceae and Staphylococcaceae families were the most predominant. A total of 132 microbial genera were detected, with Streptococcus being the predominant genus in outpatients, in contrast to hospitalized patients, in whom the Staphylococcus genus was predominant. LeFSe analysis identified 57 microbial species in the oropharyngeal washings of study participants that could discriminate the severity of symptoms of COVID-19 infections. Alpha diversity analysis did not reveal a difference in the abundance of bacterial species between the groups, but beta diversity analysis established distinct microbial communities between inpatients and outpatients. Our study provides information on the complex association between the oropharyngeal microbiota and SARS-CoV-2 infection. Although our study cannot establish causation, knowledge of specific taxonomic changes with increasing SARS-CoV-2 infection severity can provide us with novel clues for the prognostic classification of COVID-19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
390. Discovery of Bacterial Key Genes from 16S rRNA-Seq Profiles That Are Associated with the Complications of SARS-CoV-2 Infections and Provide Therapeutic Indications.
- Author
-
Kibria, Md. Kaderi, Ali, Md. Ahad, Yaseen, Muhammad, Khan, Imran Ahmad, Bhat, Mashooq Ahmad, Islam, Md. Ariful, Mahumud, Rashidul Alam, and Mollah, Md. Nurul Haque
- Subjects
- *
BACTERIAL genes , *SARS-CoV-2 , *PATHOGENIC bacteria , *BACTERIAL diseases , *PROTEIN-protein interactions , *COVID-19 , *BACTEROIDES fragilis - Abstract
SARS-CoV-2 infections, commonly referred to as COVID-19, remain a critical risk to both human life and global economies. Particularly, COVID-19 patients with weak immunity may suffer from different complications due to the bacterial co-infections/super-infections/secondary infections. Therefore, different variants of alternative antibacterial therapeutic agents are required to inhibit those infection-causing drug-resistant pathogenic bacteria. This study attempted to explore these bacterial pathogens and their inhibitors by using integrated statistical and bioinformatics approaches. By analyzing bacterial 16S rRNA sequence profiles, at first, we detected five bacterial genera and taxa (Bacteroides, Parabacteroides, Prevotella Clostridium, Atopobium, and Peptostreptococcus) based on differentially abundant bacteria between SARS-CoV-2 infection and control samples that are significantly enriched in 23 metabolic pathways. A total of 183 bacterial genes were found in the enriched pathways. Then, the top-ranked 10 bacterial genes (accB, ftsB, glyQ, hldD, lpxC, lptD, mlaA, ppsA, ppc, and tamB) were selected as the pathogenic bacterial key genes (bKGs) by their protein–protein interaction (PPI) network analysis. Then, we detected bKG-guided top-ranked eight drug molecules (Bemcentinib, Ledipasvir, Velpatasvir, Tirilazad, Acetyldigitoxin, Entreatinib, Digitoxin, and Elbasvir) by molecular docking. Finally, the binding stability of the top-ranked three drug molecules (Bemcentinib, Ledipasvir, and Velpatasvir) against three receptors (hldD, mlaA, and lptD) was investigated by computing their binding free energies with molecular dynamic (MD) simulation-based MM-PBSA techniques, respectively, and was found to be stable. Therefore, the findings of this study could be useful resources for developing a proper treatment plan against bacterial co-/super-/secondary-infection in SARS-CoV-2 infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
391. The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4: A Proposed Mechanism for the Generation of Pathogenic Antibodies.
- Author
-
Nguyen, Thi-Huong, Chen, Li-Yu, Khan, Nida Zaman, Lindenbauer, Annerose, Bui, Van-Chien, Zipfel, Peter F., and Heinrich, Doris
- Subjects
- *
QUARTZ crystal microbalances , *SARS-CoV-2 , *IMMUNOGLOBULINS , *COVID-19 , *BLOOD coagulation factors , *ZETA potential - Abstract
Pathogenic platelet factor 4 (PF4) antibodies contributed to the abnormal coagulation profiles in COVID-19 and vaccinated patients. However, the mechanism of what triggers the body to produce these antibodies has not yet been clarified. Similar patterns and many comparable features between the COVID-19 virus and heparin-induced thrombocytopenia (HIT) have been reported. Previously, we identified a new mechanism of autoimmunity in HIT in which PF4-antibodies self-clustered PF4 and exposed binding epitopes for other pathogenic PF4/eparin antibodies. Here, we first proved that the SARS-CoV-2 spike protein (SP) also binds to PF4. The binding was evidenced by the increase in mass and optical intensity as observed through quartz crystal microbalance and immunosorbent assay, while the switching of the surface zeta potential caused by protein interactions and binding affinity of PF4-SP were evaluated by dynamic light scattering and isothermal spectral shift analysis. Based on our results, we proposed a mechanism for the generation of PF4 antibodies in COVID-19 patients. We further validated the changes in zeta potential and interaction affinity between PF4 and SP and found that their binding mechanism differs from ACE2–SP binding. Importantly, the PF4/SP complexes facilitate the binding of anti-PF4/Heparin antibodies. Our findings offer a fresh perspective on PF4 engagement with the SARS-CoV-2 SP, illuminating the role of PF4/SP complexes in severe thrombotic events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
392. Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein.
- Author
-
D'Acunto, Emanuela, Muzi, Alessia, Marchese, Silvia, Donnici, Lorena, Chiarini, Valerio, Bucci, Federica, Pavoni, Emiliano, Ferrara, Fabiana Fosca, Cappelletti, Manuela, Arriga, Roberto, Serrao, Silvia Maria, Peluzzi, Valentina, Principato, Eugenia, Compagnone, Mirco, Pinto, Eleonora, Luberto, Laura, Stoppoloni, Daniela, Lahm, Armin, Groß, Rüdiger, and Seidel, Alina
- Subjects
- *
MONOCLONAL antibodies , *SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *RECOMBINANT proteins , *IMMUNOGLOBULINS , *HUMORAL immunity - Abstract
The COVID-19 pandemic, once a global crisis, is now largely under control, a testament to the extraordinary global efforts involving vaccination and public health measures. However, the relentless evolution of SARS-CoV-2, leading to the emergence of new variants, continues to underscore the importance of remaining vigilant and adaptable. Monoclonal antibodies (mAbs) have stood out as a powerful and immediate therapeutic response to COVID-19. Despite the success of mAbs, the evolution of SARS-CoV-2 continues to pose challenges and the available antibodies are no longer effective. New variants require the ongoing development of effective antibodies. In the present study, we describe the generation and characterization of neutralizing mAbs against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein by combining plasmid DNA and recombinant protein vaccination. By integrating genetic immunization for rapid antibody production and the potent immune stimulation enabled by protein vaccination, we produced a rich pool of antibodies, each with unique binding and neutralizing specificities, tested with the ELISA, BLI and FACS assays and the pseudovirus assay, respectively. Here, we present a panel of mAbs effective against the SARS-CoV-2 variants up to Omicron BA.1 and BA.5, with the flexibility to target emerging variants. This approach ensures the preparedness principle is in place to address SARS-CoV-2 actual and future infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
393. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
- Author
-
Sohail, Muhammad Saqib, Ahmed, Syed Faraz, Quadeer, Ahmed Abdul, and McKay, Matthew R.
- Subjects
- *
T cells , *SARS-CoV-2 , *SARS-CoV-2 Omicron variant , *CELLULAR recognition , *BOOSTER vaccines , *CROSS reactions (Immunology) - Abstract
The SARS-CoV-2 Omicron sub-variants BA.2.86 and JN.1 contain multiple mutations in the spike protein that were not present in previous variants of concern and Omicron sub-variants. Preliminary research suggests that these variants reduce the neutralizing capability of antibodies induced by vaccines, which is particularly significant for JN.1. This raises concern as many widely deployed COVID-19 vaccines are based on the spike protein of the ancestral Wuhan strain of SARS-CoV-2. While T cell responses have been shown to be robust against previous SARS-CoV-2 variants, less is known about the impact of mutations in BA.2.86 and JN.1 on T cell responses. We evaluate the effect of mutations specific to BA.2.86 and JN.1 on experimentally determined T cell epitopes derived from the spike protein of the ancestral Wuhan strain and the spike protein of the XBB.1.5 strain that has been recommended as a booster vaccine. Our data suggest that BA.2.86 and JN.1 affect numerous T cell epitopes in spike compared to previous variants; however, the widespread loss of T cell recognition against these variants is unlikely. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
394. Editorial for SARS-CoV-2 and COVID-19 Topical Collection.
- Author
-
Martinez-Sobrido, Luis and Almazán, Fernando
- Subjects
- *
SARS-CoV-2 , *MONOCLONAL antibodies , *VIRAL antibodies , *SARS-CoV-2 Delta variant , *SARS-CoV-2 Omicron variant , *COVID-19 - Abstract
This document is a collection of research articles focused on the study of SARS-CoV-2, the virus responsible for COVID-19. The articles cover a wide range of topics, including the molecular biology of the virus, its transmission and replication, interactions with the host, pathogenesis, epidemiology, and the development of vaccines and antiviral treatments. The goal of the collection is to provide up-to-date insights into SARS-CoV-2 and COVID-19, stimulating further research to improve prevention and treatment strategies. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
395. Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2.
- Author
-
Gentile, Davide, Chiummiento, Lucia, Santarsiere, Alessandro, Funicello, Maria, Lupattelli, Paolo, Rescifina, Antonio, Venuti, Assunta, Piperno, Anna, Sciortino, Maria Teresa, and Pennisi, Rosamaria
- Subjects
- *
SARS-CoV-2 , *CYSTEINE proteinases , *CATHEPSIN B , *SARS-CoV-2 Omicron variant , *COVID-19 pandemic , *PROTEOLYTIC enzymes - Abstract
The continuous emergence of SARS-CoV-2 variants caused the persistence of the COVID-19 epidemic and challenged the effectiveness of the existing vaccines. The viral proteases are the most attractive targets for developing antiviral drugs. In this scenario, our study explores the use of HIV-1 protease inhibitors against SARS-CoV-2. An in silico screening of a library of HIV-1 proteases identified four anti-HIV compounds able to interact with the 3CLpro of SARS-CoV-2. Thus, in vitro studies were designed to evaluate their potential antiviral effectiveness against SARS-CoV-2. We employed pseudovirus technology to simulate, in a highly safe manner, the adsorption of the alpha (α-SARS-CoV-2) and omicron (ο-SARS-CoV-2) variants of SARS-CoV-2 and study the inhibitory mechanism of the selected compounds for cell–virus interaction. The results reported a mild activity against the viral proteases 3CLpro and PLpro, but efficient inhibitory effects on the internalization of both variants mediated by cathepsin B/L. Our findings provide insights into the feasibility of using drugs exhibiting antiviral effects for other viruses against the viral and host SARS-CoV-2 proteases required for entry. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
396. In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants.
- Author
-
Wei, Calvin R., Basharat, Zarrin, and Lang'at, Godwin C.
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *COMPUTER-assisted drug design , *DRUG repositioning , *SARS-CoV-2 Omicron variant - Abstract
COVID-19 has claimed around 7 million lives (from December 2019–November 2023) worldwide and continues to impact global health. SARS-CoV-2, the virus causing COVID-19 disease, is characterized by a high rate of mutations, which contributes to its rapid spread, virulence, and vaccine escape. While several vaccines have been produced to minimize the severity of the coronavirus, and diverse treatment regimens have been approved by the US FDA under Emergency Use Authorization (EUA), SARS-CoV-2 viral mutations continue to derail the efforts of scientists as the emerging variants evade the recommended therapies. Nonetheless, diverse computational models exist that offer an opportunity for the swift development of new drugs or the repurposing of old drugs. In this review, we focus on the use of various virtual screening techniques like homology modeling, molecular docking, molecular dynamics simulations, QSAR, pharmacophore modeling, etc., in repurposing SARS-CoV-2 therapeutics against major variants of SARS-CoV-2 (Alpha, Beta, Gamma, Delta, and Omicron). The results have been promising from the computer-aided drug design (CADD) studies in suggesting potential compounds for the treatment of COVID-19 variants. Hence, in silico therapeutic studies represent a transformative approach that holds great promise in advancing our fight against the ever-evolving landscape of SARS-CoV-2 and its variants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
397. COVID-19 Epidemic Process and Evolution of SARS-CoV-2 Genetic Variants in the Russian Federation.
- Author
-
Akimkin, Vasiliy, Semenenko, Tatiana A., Ugleva, Svetlana V., Dubodelov, Dmitry V., and Khafizov, Kamil
- Subjects
- *
COVID-19 pandemic , *SARS-CoV-2 , *SARS-CoV-2 Omicron variant , *SARS-CoV-2 Delta variant , *COVID-19 , *GENETIC variation - Abstract
The COVID-19 pandemic, etiologically related to a new coronavirus, has had a catastrophic impact on the demographic situation on a global scale. The aim of this study was to analyze the manifestations of the COVID-19 epidemic process, the dynamics of circulation, and the rate of the spread of new variants of the SARS-CoV-2 virus in the Russian Federation. Retrospective epidemiological analysis of COVID-19 incidence from March 2020 to fall 2023 and molecular genetic monitoring of virus variability using next-generation sequencing technologies and bioinformatics methods were performed. Two phases of the pandemic, differing in the effectiveness of anti-epidemic measures and the evolution of the biological properties of the pathogen, were identified. Regularities of SARS-CoV-2 spread were determined, and risk territories (megacities), risk groups, and factors influencing the development of the epidemic process were identified. It was found that with each subsequent cycle of disease incidence rise, the pathogenicity of SARS-CoV-2 decreased against the background of the increasing infectiousness of SARS-CoV-2. Data on the mutational variability of the new coronavirus were obtained using the Russian platform of viral genomic information aggregation (VGARus) deployed at the Central Research Institute of Epidemiology. Monitoring the circulation of SARS-CoV-2 variants in Russia revealed the dominance of Delta and Omicron variants at different stages of the pandemic. Data from molecular genetic studies are an essential component of epidemiologic surveillance for making management decisions to prevent the further spread of SARS-CoV-2 and allow for prompt adaptation to pandemic control tactics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
398. Interferon- γ as a Potential Inhibitor of SARS-CoV-2 ORF6 Accessory Protein.
- Author
-
Krachmarova, Elena, Petkov, Peicho, Lilkova, Elena, Stoynova, Dayana, Malinova, Kristina, Hristova, Rossitsa, Gospodinov, Anastas, Ilieva, Nevena, Nacheva, Genoveva, and Litov, Leandar
- Subjects
- *
INTERFERONS , *SARS-CoV-2 , *TYPE I interferons , *GENE expression , *CELL membranes , *DNA replication , *PROTEINS - Abstract
The ORF6 protein of the SARS-CoV-2 virus plays a crucial role in blocking the innate immune response of the infected cells by inhibiting interferon pathways. Additionally, it binds to and immobilises the RAE1 protein on the cytoplasmic membranes, thereby blocking mRNA transport from the nucleus to the cytoplasm. In all these cases, the host cell proteins are tethered by the flexible C-terminus of ORF6. A possible strategy to inhibit the biological activity of ORF6 is to bind its C-terminus with suitable ligands. Our in silico experiments suggest that hIFN γ binds the ORF6 protein with high affinity, thus impairing its interactions with RAE1 and, consequently, its activity in viral invasion. The in vitro studies reported here reveal a shift of the localisation of RAE1 in ORF6 overexpressing cells upon treatment with hIFN γ from predominantly cytoplasmic to mainly nuclear, resulting in the restoration of the export of mRNA from the nucleus. We also explored the expression of GFP in transfected-with-ORF6 cells by means of fluorescence microscopy and qRT-PCR, finding that treatment with hIFN γ unblocks the mRNA trafficking and reinstates the GFP expression level. The ability of the cytokine to block ORF6 is also reflected in minimising its negative effects on DNA replication by reducing accumulated RNA-DNA hybrids. Our results, therefore, suggest hIFN γ as a promising inhibitor of the most toxic SARS-CoV-2 protein. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
399. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.
- Author
-
Pavan, María Florencia, Bok, Marina, Betanzos San Juan, Rafael, Malito, Juan Pablo, Marcoppido, Gisela Ariana, Franco, Diego Rafael, Militelo, Daniela Ayelen, Schammas, Juan Manuel, Bari, Sara Elizabeth, Stone, William, López, Krisangel, Porier, Danielle LaBrie, Muller, John Anthony, Auguste, Albert Jonathan, Yuan, Lijuan, Wigdorovitz, Andrés, Parreño, Viviana Gladys, and Ibañez, Lorena Itat
- Subjects
- *
TRANSGENIC mice , *SARS-CoV-2 Omicron variant , *MICE , *IMMUNOGLOBULINS , *SARS-CoV-2 , *VIRAL antibodies , *TURBINATE bones , *COVID-19 treatment , *INTRANASAL administration - Abstract
Since the beginning of the COVID-19 pandemic, there has been a significant need to develop antivirals and vaccines to combat the disease. In this work, we developed llama-derived nanobodies (Nbs) directed against the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Most of the Nbs with neutralizing properties were directed to RBD and were able to block S-2P/ACE2 interaction. Three neutralizing Nbs recognized the N-terminal domain (NTD) of the S-2P protein. Intranasal administration of Nbs induced protection ranging from 40% to 80% after challenge with the WA1/2020 strain in k18-hACE2 transgenic mice. Interestingly, protection was associated with a significant reduction in virus replication in nasal turbinates and a reduction in virus load in the brain. Employing pseudovirus neutralization assays, we identified Nbs with neutralizing capacity against the Alpha, Beta, Delta, and Omicron variants, including a Nb capable of neutralizing all variants tested. Furthermore, cocktails of different Nbs performed better than individual Nbs at neutralizing two Omicron variants (B.1.529 and BA.2). Altogether, the data suggest the potential of SARS-CoV-2 specific Nbs for intranasal treatment of COVID-19 encephalitis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
400. Prompt Placental Histopathological and Immunohistochemical Assessment after SARS-CoV-2 Infection during Pregnancy—Our Perspective of a Small Group.
- Author
-
Popescu, Daniela Eugenia, Roșca, Ioana, Jura, Ana Maria Cristina, Cioca, Andreea, Pop, Ovidiu, Lungu, Nicoleta, Popa, Zoran-Laurențiu, Rațiu, Adrian, and Boia, Mărioara
- Subjects
- *
SARS-CoV-2 , *PLACENTA , *THIRD trimester of pregnancy , *FIBRIN , *UMBILICAL cord , *MECONIUM , *HISTOPATHOLOGY - Abstract
Research indicates compelling evidence of SARS-CoV-2 vertical transmission as a result of placental pathology. This study offers an approach to histopathological and immunohistochemical placental observations from SARS-CoV-2-positive mothers compared to negative ones. Out of the 44 examined placentas, 24 were collected from patients with a SARS-CoV-2 infection during pregnancy and 20 were collected from patients without infection. The disease group showed strong SARS-CoV-2 positivity of the membranes, trophoblasts, and fetal villous macrophages. Most infections occurred during the third trimester of pregnancy (66.6%). Pathology revealed areas consistent with avascular villi (AV) and thrombi in the chorionic vessels and umbilical cord in the positive group, suggesting fetal vascular malperfusion (FVM). This study shows SARS-CoV-2 has an impact on coagulation, demonstrated by fetal thrombotic vasculopathy (p = 0.01) and fibrin deposition (p = 0.01). Other observed features included infarction (17%), perivillous fibrin deposition (29%), intervillous fibrin (25%), delayed placental maturation (8.3%), chorangiosis (13%), chorioamnionitis (8.3%), and meconium (21%). The negative control group revealed only one case of placental infarction (5%), intervillous fibrin (5%), delayed placental maturation (5%), and chorioamnionitis (5%) and two cases of meconium (19%). Our study sheds light on the changes and differences that occurred in placentas from SARS-CoV-2-infected mothers and the control group. Further research is necessary to definitively establish whether SARS-CoV-2 is the primary culprit behind these intricate complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.